Abstract
Objective To investigate brain injury markers (BIM), endothelial injury markers (EIM) and cytokine/chemokine (CC) markers of systemic inflammation in coronavirus disease 2019 (COVID-19) and across sex.
Methods Plasma samples from 57 subjects at <48 hours of COVID-19 hospitalization, 14 subjects at 3 months of COVID-19 hospitalization and 20 matched controls were interrogated for the levels of six BIMs - including GFAP, S100B, Syndecan-1, UCHLI, MAP2 and NSE, two EIMs – including sICAM1 and sVCAM1 and thirty-eight CCs. Statistical and bioinformatics methods were used to measure differences in the marker profiles across (a) COVID-19 vs controls and (b) men vs women.
Results Three BIMs: MAP2, NSE and S100B, two EIMs: sICAM1 and sVCAM1 and seven CCs: GRO IL10, sCD40L, IP10, IL1Ra, MCP1 and TNFα were significantly (p<0.05) elevated in the COVID-19 cohort compared to controls. Two CCs: MDC and MIP1α were significantly lower in the COVID-19 cohort. Bioinformatics analysis reveal a stronger positive association between BIM/CC/EIMs in the COVID-19 cohort. Analysis across sex revealed that several BIMs and CCs including NSE, IL10, IL15 and IL8 were significantly (p<0.05) higher in men compared to women. Men also expressed a more robust BIM/ EIM/CC association profile compared to women. At 3 months, BIMs and CCs were not significantly different in the COVID-19 cohort compared to controls.
Conclusion The acute elevation of BIMs, CCs, and EIMs and the robust associations among them at COVID-19 hospitalization suggest that brain injury is mediated by endotheliopathy and inflammation. Higher BIM and inflammatory markers in men additionally suggest that men are more susceptible to the risk compared to women.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
. This work was partly supported by an award from the Huffington Foundation to Dr. Louise D. McCullough. We thank The Biorepository of Neurological Diseases team for their efforts in collecting the samples.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board (IRB No HSC MH 17 0452) at The University of Texas Health Science Center at Houston, Houston, Texas
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Contributions: JS, LM, PD and HAC were involved in the conception and design of the study. JS was involved in analysis of data. EP, GC, SH, DM, HA, AP, AA and SJ and were involved in the acquisition of data. JS, EP, EK, SC, AG, PD, LM and HAC contributed substantially in drafting the manuscript and figures.
Potential Conflicts of Interest: None
Data Availability
Upon request.
